Global Cord Blood Corporation (CORBF) Fair Value & Analysis
Healthcare · US · Market cap $141M · ISIN US6986591096
Global Cord Blood Corporation
CORBF · US
Strengths
Risks
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 15 days ago
Fair value updated Aug 13, 2026, revised from $0.7445 to $0.7565 (+1.6%) since Jul 15, 2026.
A solid business, but trading 26% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- Our model range runs from $0.6363 (bear) to $0.9455 (bull), base $0.7565. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 72/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.2000 – $6.22 · fair‑value band $0.6363 – $0.9455 · the $0.9500 price screens above the $0.7565 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Global Cord Blood Corporation (CORBF) currently trades at $0.9500, while our model-based Fair Value estimate is $0.7565, implying the stock looks roughly 20.4% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Global Cord Blood Corporation generated revenue of $1.2B at a net margin of 40.3%. Revenue declined 1.7% year over year. It earns a return on equity of 11.0%. The balance sheet holds a net cash position of $6.7B. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.6363 (bear case) to $0.9455 (bull case); at $0.9500, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high and 375% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -20%, CORBF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models ($1.20) versus Asset-Based ($0.2246). Highest evidence: Growth DCF (80).
Notify me when CORBF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.
Full company description
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
Global Cord Blood Corporation reported revenue of ¥1.2B in FY2022 versus ¥937M in FY2018, a compound +7.3%/yr. Reported net income was ¥501M in FY2022, compounding +20.6%/yr from FY2018.
of which total revenue +12.6 pp · buybacks/dilution −6.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
CORBF screens 20% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 140 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | -51% |
| Danaher Corporation DHR | $215.68 | $103.88 | -52% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 587.80 | CHF 259.80 | -56% |
| IDEXX Laboratories, Inc IDXX | $553.44 | $255.77 | -54% |
| Agilent Technologies, Inc A | $155.08 | $61.53 | -60% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $224.84 | $95.51 | -58% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare Global Cord Blood Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Global Cord Blood Corporation (CORBF) overvalued or undervalued?
What is the fair value of CORBF?
What is the quality score of CORBF?
What is the revenue of Global Cord Blood Corporation (CORBF)?
What is the net profit margin of CORBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Global Cord Blood Corporation in the live analysis
One click puts Global Cord Blood Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.